Regulatory

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

BioSpace

Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk's semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials.

Metabolic & GLP-1

Read full story

pharminent June 9, 2026 (Last updated: June 9, 2026)

BioSpace

Newly approved weight loss pill Foundayo reduced blood sugar more than Novo Nordisk’s semaglutide and other comparators in multiple Phase 3 type 2 diabetes trials.

Metabolic & GLP-1

Read full story

Related Stories

Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

You May Have Missed

Alzecure enters collaboration and with Lilly for Alzheimer’s project

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval